Multicomponent mapping of boron chemotypes furnishes selective enzyme inhibitors

Nature Communications

Volumn 8, Issue 1, 2017, Pages

  Tan, Joanne ^a   Iii, Armand B Cognetta ^b   Diaz, Diego B ^a   Lum, Kenneth M ^b   Adachi, Shinya ^a   Kundu, Soumajit ^b   Cravatt, Benjamin F ^b   Yudin, Andrei K ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA AMINOBORONIC ACID; BORONIC ACID DERIVATIVE; CARBONYL DERIVATIVE; ENZYME INHIBITOR; HYDROLASE; ORGANOBORON DERIVATIVE; UNCLASSIFIED DRUG; BORON; BORON DERIVATIVE;

BORON; CELLS AND CELL COMPONENTS; CHEMICAL COMPOUND; ENZYME; ENZYME ACTIVITY; INHIBITOR; MAPPING METHOD; PROTEIN;

ARTICLE; CONTROLLED STUDY; CROSS REACTION; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC50; METABOLOMICS; STRUCTURE ACTIVITY RELATION; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM; SYNTHESIS;

BORON; BORON COMPOUNDS; ENZYME INHIBITORS; HUMANS; MOLECULAR STRUCTURE;

EID: 85034947197     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-017-01319-4     Document Type: Article

References (45)

1. Adamczyk-Woźniak, A., Borys, K. M. & Sporzyński, A. Recent developments in the chemistry and biological applications of benzoxaboroles. Chem. Rev. 115, 5224-5247 (2015).
2. Baker, S. J. et al. Therapeutic potential of boron-containing compounds. Future Med. Chem. 1, 1275-1288 (2009).
3. Baker, S. J., Tomsho, J. W. & Benkovic, S. J. Boron-containing inhibitors of synthetases. Chem. Soc. Rev. 40, 4279-4285 (2011).
4. Das, B. C. et al. Boron chemicals in diagnosis and therapeutics. Future Med. Chem. 5, 653-676 (2013).
5. Smoum, R., Rubinstein, A., Dembitsky, V. M. & Srebnik, M. Boron containing compounds as protease inhibitors. Chem. Rev. 112, 4156-4220 (2012).
6. Touchet, S., Carreaux, F., Carboni, B., Bouillon, A. & Boucher, J.-L. Aminoboronic acids and esters: From synthetic challenges to the discovery of unique classes of enzyme inhibitors. Chem. Soc. Rev. 40, 3895-3914 (2011).
7. Bross, P. F. et al. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin. Cancer. Res. 10, 3954-3964 (2004).
8. Kupperman, E. et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 70, 1970-1980 (2010).
9. Gallerani, E. et al. A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma. Eur. J. Cancer 49, 290-296 (2013).
10. Yang, W., Gao, X. & Wang, B. Boronic acid compounds as potential pharmaceutical agents. Med. Res. Rev. 23, 346-368 (2003).
11. Diaz, D. B. & Yudin, A. K. The versatility of boron in biological target engagement. Nat. Chem. 9, 731-742 (2017).
12. Borissenko, L. & Groll, M. 20S protasome and its inhibitors: Crystallographic knowledge for drug development. Chem. Rev. 107, 687-717 (2007).
13. Groll, M., Huber, R. & Moroder, L. The persisting challenge of selective and specific proteasome inhibition. J. Pept. Sci. 15, 58-66 (2009).
14. Powers, J. C., Asgian, J. L., Ekici, Ö. D. & James, K. E. Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem. Rev. 102, 4639-4750 (2002).
15. Laplante, C. & Hall, D. G. Direct mono-N-methylation of solid-supported amino acids: A useful application of the Matteson rearrangement of α-aminoalkylboronic esters. Org. Lett. 3, 1487-1490 (2001).
16. Matteson, D. S. & Sadhu, K. M. Synthesis of 1-amino-2-phenylethane-1-boronic acid derivatives. Organometallics. 3, 614-618 (1984).
17. Seebach, D., Beck, A. K. & Bierbaum, D. J. The world of β-and γ-peptides comprised of homologated proteinogenic amino acids and other components. Chem. Biodivers. 1, 1111-1239 (2004).
18. Takashiro, E. et al. Structure-activity relationship of HIV-1 protease inhibitors containing α-hydroxy-β-amino acids. Detailed study of P1 site. Bioorganic Med. Chem. 7, 2063-2072 (1999).
19. Zajdlik, A. et al. α-Boryl isocyanides enable facile preparation of bioactive boropeptides. Angew. Chem. Int. Ed. 52, 8411-8415 (2013).
20. Adachi, S. et al. Facile synthesis of borofragments and their evaluation in activity-based protein profiling. Chem. Commun. 51, 3608-3611 (2015).
21. Diaz, D. B. et al. Synthesis of aminoboronic acid derivatives from amines and amphoteric boryl carbonyl compounds. Angew. Chemie Int. Ed. 55, 12659-12663 (2016).
22. Fleming, F. F., Yao, L., Ravikumar, P. C., Funk, L. & Shook, B. C. Nitrile-containing pharmaceuticals: Efficacious roles of the nitrile pharmacophore. J. Med. Chem. 53, 7902-7917 (2010).
23. Sakamoto, K. & Nakamura, Y. Urinary metabolites of pinacidil: I. Isolation and identification of the metabolites in rat urine. Xenobiotica. 23, 391-400 (1993).
24. Sakamoto, K. & Nakamura, Y. Urinary metabolites of pinacidil. II. Species difference in the metabolism of pinacidil. Xenobiotica 23, 649-656 (1993).
25. Terashita, S. et al. Metabolism of nilvadipine, a new dihydropyridine calcium antagonist, in rats and dogs. Xenobiotica. 17, 1415-1425 (1987).
26. 14C]lersivirine to healthy volunteers. Drug Metab. Dispos. 38, 789-800 (2010).
27. Eliel, E. L., Wilen, S. H. & Mander, L. N. Stereochemistry of Organic Compounds (Wiley, 1994).
28. Teno, N. et al. Novel scaffold for cathepsin K inhibitors. Bioorganic Med. Chem. Lett. 17, 6096-6100 (2007).
29. He, Z. & Yudin, A. K. Amphoteric α-boryl aldehydes. J. Am. Chem. Soc. 133, 13770-13773 (2011).
30. 3) boronate building blocks. J. Am. Chem. Soc. 133, 13774-13777 (2011).
31. St. Denis, J. D. et al. Boron-containing enamine and enamide linchpins in the synthesis of nitrogen heterocycles. J. Am. Chem. Soc. 136, 17669-17673 (2014).
32. He, Z. et al. Oxidative geminal functionalization of organoboron compounds. Angew. Chem. Int. Ed. 51, 11092-11096 (2012).
33. Garrett, G. E., Diaz, D. B., Yudin, A. K. & Taylor, M. S. β-aminoboronic acids with carbohydrate derivatives. Chem. Commun. 53, 1809-1812 (2017).
34. Pan, S. & List, B. Catalytic one-pot, three-component acyl-strecker reaction. Synlett. 2, 318-320 (2007).
35. 3N-catalyzed three-component condensation of aldehydes, amines and cyanides: a high yielding synthesis of α-aminonitriles. Tetrahedron Lett. 47, 5759-5762 (2006).
36. Long, J. Z. & Cravatt, B. F. The metabolic serine hydrolases and their functions in mammalian physiology and disease. Chem. Rev. 111, 6022-6063 (2011).
37. Niphakis, M. J. & Cravatt, B. F. Enzyme inhibitor discovery by activity-based protein profiling. Annu. Rev. Biochem. 83, 341-377 (2014).
38. Cognetta, A. B. III et al. Selective N-hydroxyhydantoin carbamate inhibitors of mammalian serine hydrolases. Chem. Biol. 22, 928-937 (2015).
39. Shah, P. & Westwell, A. D. The role of fluorine in medicinal chemistry. J. Enzyme Inhib. Med. Chem. 22, 527-540 (2007).
40. Long, J. Z. et al. Metabolomics annotates ABHD3 as a physiologic regulator of medium-chain phospholipids. Nat. Chem. Biol. 7, 763-765 (2011).
41. Adibekian, A. et al. Click-generated triazole ureas as ultrapotent in vivo-active serine hydrolase inhibitors. Nat. Chem. Biol. 7, 469-478 (2011).
42. Ong, S. & Mann, M. A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC). Nat. Protoc. 1, 2650-2660 (2007).
43. Edwards, A. M., Bountra, C., Kerr, D. J. & Willson, T. M. Open access chemical and clinical probes to support drug discovery. Nat. Chem. Biol. 5, 436-440 (2009).
44. Saghatelian, A. et al. Assignment of endogenous substrates to enzymes by global metabolite profiling. Biochemistry 43, 14332-14339 (2004).
45. Lee, H., Simon, G. M. & Cravatt, B. F. ABHD4 regulates multiple classes of N-acyl phospholipids in the mammalian central nervous system. Biochemistry 54, 2539-2549 (2015).